Zentalis Pharmaceuticals (NASDAQ:ZNTL) Rating Reiterated by HC Wainwright

Zentalis Pharmaceuticals (NASDAQ:ZNTL)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research report issued on Monday, Benzinga reports. They presently have a $20.00 price target on the stock.

A number of other research firms have also commented on ZNTL. Jefferies Financial Group reaffirmed a “hold” rating and issued a $6.00 price target (down from $42.00) on shares of Zentalis Pharmaceuticals in a report on Tuesday, June 18th. Morgan Stanley reissued an “equal weight” rating and issued a $8.00 price target (down previously from $38.00) on shares of Zentalis Pharmaceuticals in a research note on Tuesday, June 18th. Oppenheimer dropped their price objective on shares of Zentalis Pharmaceuticals from $50.00 to $25.00 and set an “outperform” rating for the company in a report on Tuesday, June 18th. UBS Group cut Zentalis Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $28.00 to $5.00 in a report on Thursday, June 20th. Finally, Wedbush cut Zentalis Pharmaceuticals from a “neutral” rating to an “underperform” rating and decreased their price objective for the company from $15.00 to $4.00 in a report on Tuesday, June 18th. Seven analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $11.33.

Zentalis Pharmaceuticals Stock Performance

Shares of NASDAQ ZNTL opened at $3.03 on Monday. The stock has a market cap of $215.22 million, a price-to-earnings ratio of -0.91 and a beta of 1.70. Zentalis Pharmaceuticals has a fifty-two week low of $2.96 and a fifty-two week high of $29.03. The firm’s 50-day simple moving average is $5.05 and its 200 day simple moving average is $10.22.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its earnings results on Friday, August 9th. The company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.40). During the same quarter in the prior year, the firm posted ($1.85) EPS. On average, sell-side analysts predict that Zentalis Pharmaceuticals will post -2.72 EPS for the current year.

Insider Activity at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, CFO Cam Gallagher sold 9,597 shares of Zentalis Pharmaceuticals stock in a transaction that occurred on Friday, May 31st. The stock was sold at an average price of $11.98, for a total transaction of $114,972.06. Following the sale, the chief financial officer now directly owns 633,680 shares of the company’s stock, valued at approximately $7,591,486.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 6.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the stock. Eventide Asset Management LLC boosted its stake in Zentalis Pharmaceuticals by 47.9% during the 4th quarter. Eventide Asset Management LLC now owns 11,559,975 shares of the company’s stock valued at $175,134,000 after purchasing an additional 3,745,936 shares during the last quarter. Decheng Capital LLC purchased a new stake in shares of Zentalis Pharmaceuticals during the fourth quarter valued at $31,809,000. Price T Rowe Associates Inc. MD increased its holdings in Zentalis Pharmaceuticals by 20.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,489,709 shares of the company’s stock worth $54,999,000 after buying an additional 585,644 shares in the last quarter. Renaissance Technologies LLC raised its position in Zentalis Pharmaceuticals by 152.6% in the 2nd quarter. Renaissance Technologies LLC now owns 661,682 shares of the company’s stock worth $2,706,000 after buying an additional 399,745 shares during the last quarter. Finally, Federated Hermes Inc. lifted its stake in Zentalis Pharmaceuticals by 10.9% during the 4th quarter. Federated Hermes Inc. now owns 2,160,565 shares of the company’s stock valued at $32,733,000 after acquiring an additional 212,872 shares during the period.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.